Plain-English translation of NCT04317534 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called , given after surgery to remove early-stage lung cancer, can help keep the cancer from returning. Half of the participants will receive the medication as a series of injections over 9 months, while the other half will receive no additional treatment after surgery and simply be monitored closely.
Even after successful surgery for early-stage lung cancer, some patients experience cancer recurrence. Researchers want to know if this medication can boost the immune system to fight any remaining cancer cells and improve long-term survival.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to one of two groups. One group receives intravenous infusions of the medication every 6 weeks for 9 cycles (about 9 months total), while the other group simply comes in for regular check-ups and imaging scans to watch for any signs of cancer return. Regardless of which group you're in, you'll have clinic visits and CT scans at set intervals over the following years to monitor your health.
AI-generated summary from trial data · Aug 1, 2026 · Not medical advice
United States